P4P4P: An Agenda For Research On Pay-For-Performance For Patients

Center for Health Incentives, Leonard Davis Institute of Health Economics, Wharton School, University of Pennsylvania, USA.
Health Affairs (Impact Factor: 4.64). 01/2009; 28(1):206-14. DOI: 10.1377/hlthaff.28.1.206
Source: PubMed

ABSTRACT Unhealthy behavior is a major cause of poor health outcomes and high health care costs. In this paper we describe an agenda for research to guide broader use of patient-targeted financial incentives, either in conjunction with provider-targeted financial incentives (pay-for-performance, or P4P) or in clinical contexts where provider-targeted approaches are unlikely to be effective. We discuss evidence of proven effectiveness and limitations of the existing evidence, reasons for underuse of these approaches, and options for achieving wider use. Patient-targeted incentives have great potential, and systematic testing will help determine how they can best be used to improve population health.

Download full-text


Available from: George Loewenstein, Jul 09, 2015
1 Follower
  • Source
    • "The magnitude of the benefits and the costs from a specific incentive system will depend on the size and structure (e.g. escalating benefits) of the benefits, including: frequency of testing and paying incentives, method of testing for achievement of the outcomes (e.g., cotinine levels vs. self-report) and length of the incentive program and follow-up, among other behavioral factors (Haisley et al., 2012; Volpp et al., 2009b, 2011). Interestingly, higher and more frequent payments, more frequent testing and a longer program all increase effectiveness and benefits. "
    Preventive Medicine 06/2012; 55 Suppl:S116-7. DOI:10.1016/j.ypmed.2012.03.017 · 2.93 Impact Factor
  • Source
    • "While the use of incentives to promote engagement in HIV care and adherence with antiretroviral therapy deserves additional study, incentive-based approaches face several challenges (Volpp et al., 2009a;Schmidt et al., 2010;Marteau et al., 2009). First, some incentive-based approaches have involved large financial rewards (e.g., up to $1200 over 12 weeks), and it is not clear if allocation of healthcare resources in this way would be feasible or advisable. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Substance abuse and addiction are highly prevalent in HIV-infected individuals. Substance abuse is an important comorbidity that affects the delivery and outcomes of HIV medical management. In this paper I will review data examining the associations between substance abuse and HIV treatment and potential strategies to improve outcomes in this population that warrant further investigation. Current - but not past - substance abuse adversely affects engagement in care, acceptance of antiretroviral therapy, adherence with therapy, and long-term persistence in care. Substance abuse treatment appears to facilitate engagement in HIV care, and access to evidence-based treatment for substance abuse is central to addressing the HIV epidemic. Strategies that show promise for HIV-infected substance abusers include integrated treatment models, directly observed therapy, and incentive-based interventions.
    Life sciences 09/2010; 88(21-22):948-52. DOI:10.1016/j.lfs.2010.09.025 · 2.30 Impact Factor